Sanofi to pay $11.9 million to resolve U.S. drug kickback probe

BOSTON (Reuters) – Sanofi SA (PA:) has agreed to pay nearly $11.9 million to resolve allegations that it used a charity that helps Medicare patients cover out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of a high-priced multiple sclerosis drug.

The U.S. Justice Department on Friday said Sanofi was the latest company to settle claims stemming from an industry-wide probe of drugmakers’ financial support of patient assistance charities.

Sanofi did not admit wrongdoing as part of the settlement.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.